Syngene International Q2 FY26 Concall Decoded – Biotech’s Boring Quarter with Billion-Dollar Dreams 💊

1. Opening Hook

When your revenue grows 2% but your ambition grows 200%, you must be Syngene. The Q2 FY26 call felt like a science fair meets TED Talk — plenty of molecules, fewer miracles. CEO Peter Bains spoke like a biotech bard: “We’re building capabilities” — translation: “profits on vacation till FY27.” Still, new peptide plants, ADC expansions, and the first-ever global Phase III clinical trial kept analysts awake (barely). The big reveal? Bayview USA plant will finally go live soon — unless “commissioning” gets another definition next quarter. Stick around — things get cultured later, both literally and financially.

2. At a Glance

• Revenue ₹911 crore (↑2%) – Flat as a microscope slide, but “in line with expectations.”
• EBITDA ₹200 crore (↓18%) – Margins shrank faster than lab budgets.
• PAT ₹67 crore (↓37%) – Profit fled to a safe harbor clause.
• R&D Spend up – They’re spending like discovery is an emotion.
• CDMO share 33% (↓) – Inventory correction = polite way of saying “client didn’t order.”
• Net Cash ₹1,018 crore – Because someone has to stay solvent here.
• Guidance unchanged – The eternal “mid-20s margin, mid-single-digit growth” hymn.

3. Management’s Key Commentary

“Revenue up 2%, in line with expectations.”
(Translation: The bar was low, and we still tripped on it.)

“EBITDA margin at 22% versus 27% last year.”
(Translation: Inflation hit even our Excel sheets.)

“We won our first global Phase III trial.”
(Translation: Finally entered the big leagues — on paper. 😏)

“Bayview US facility to start operations in H2.”
(Translation: Any day now… just not today.)

“Peptide and ADC expansions will drive future growth.”
(Translation: Please ignore current growth.)

“PAT decline due to higher depreciation and hedge losses.”
(Translation: Accounting alchemy meets bad FX luck.)

“FY26 remains a ‘transient year.’”
(Translation: Don’t judge us till FY27.)

4. Numbers Decoded